These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 18375647)

  • 61. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 62. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
    Sambucini V
    Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Integrated phase II/III clinical trials in oncology: a case study.
    Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
    Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.
    Chen DT; Schell MJ; Fulp WJ; Pettersson F; Kim S; Gray JE; Haura EB
    Transl Cancer Res; 2019 Jul; 8(Suppl 4):S404-S420. PubMed ID: 31456910
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bayesian two-stage designs for phase II clinical trials.
    Tan SB; Machin D
    Stat Med; 2002 Jul; 21(14):1991-2012. PubMed ID: 12111883
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II trials powered to detect tumor subtypes.
    Roberts JD; Ramakrishnan V
    Clin Cancer Res; 2011 Sep; 17(17):5538-45. PubMed ID: 21737510
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
    Sambucini V
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A modified varying-stage adaptive phase II/III clinical trial design.
    Dong G; Vandemeulebroecke M
    Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.
    Wu Y; Shih WJ
    Stat Med; 2008 Dec; 27(29):6190-208. PubMed ID: 18800338
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.
    Broglio K; Meurer WJ; Durkalski V; Pauls Q; Connor J; Berry D; Lewis RJ; Johnston KC; Barsan WG
    JAMA Netw Open; 2022 May; 5(5):e2211616. PubMed ID: 35544137
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy.
    DeVeaux M; Kane M; Wei W; Zelterman D
    Pharm Stat; 2019 Nov; 18(6):700-713. PubMed ID: 31507079
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
    Grayling MJ; Mander AP
    BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
    Guo B; Liu S
    Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
    Kunz CU; Kieser M
    Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Suspension of accrual in phase II cancer clinical trials.
    Li Y; Mick R; Heitjan DF
    Clin Trials; 2015 Apr; 12(2):128-38. PubMed ID: 25568092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.